31 Tributyltin (TBT), a peroxisome proliferator-activated receptor γ (PPARγ)/retinoid X receptor 32 (RXR) ligand and founding member of the environmental obesogen chemical class, induces 33 adipocyte differentiation and suppresses bone formation. A growing number of environmental 34 PPARγ ligands are being identified. However, the potential for environmental PPARγ ligands to 35 induce adverse metabolic effects has been questioned because PPARγ is a therapeutic target in 36 treatment of type II diabetes. We evaluated the molecular consequences of TBT exposure during 37 bone marrow multipotent mesenchymal stromal cell (BM-MSC) differentiation in comparison to 38 rosiglitazone, a therapeutic PPARγ ligand, and LG100268, a synthetic RXR ligand. Mouse 39 primary BM-MSCs (female, C57BL/6J) undergoing bone differentiation were exposed to 40 maximally efficacious and human relevant concentrations of rosiglitazone (100 nM), LG100268 41 (100 nM) or TBT (80 nM) for 4 days. Gene expression was assessed using microarrays, and in 42 silico functional annotation was performed using pathway enrichment analysis approaches. 43 Pathways related to osteogenesis were downregulated by all three ligands, while pathways 44 related to adipogenesis were upregulated by rosiglitazone and TBT. However, pathways related 45 to mitochondrial biogenesis and brown-in-white (brite) adipocyte differentiation were more 46 significantly upregulated in rosiglitazone-treated than TBT-treated cells. The lack of induction of 47 genes involved in adipocyte energy dissipation by TBT was confirmed by an independent gene 48 expression analysis in BM-MSCs undergoing adipocyte differentiation and by analysis of a 49 publically available 3T3 L1 data set. Furthermore, rosiglitazone, but not TBT, induced 50 mitochondrial biogenesis. This study is the first to show that an environmental PPARγ ligand has 51 a limited capacity to induce health promoting activities of PPARγ. 52 highly potent PPARγ ligand, which induces differentiation of bone marrow and adipose-derived 76 multipotent stromal cells (MSCs) into adipocytes and suppresses bone formation (Baker et al. 77
Introduction 53
Metabolic disruptors are chemicals that play a role in altering susceptibility to obesity, 54 metabolic syndrome and related metabolic disorders including type 2 diabetes (Heindel, et al., the cultures were re-dosed. On days 5 and 7 of differentiation, the adipocyte maintenance 145 medium was replaced and the cultures re-dosed. Following 5 or 10 days of differentiation, cells 146 were harvested for analysis of mRNA expression, lipid accumulation, and mitochondrial 147 biogenesis analyses.
148
Microarray data preprocessing and filtering. Microarray data processing and analyses 149 were performed in R software (version 3.3.1). Affymetrix CEL files were processed using the 150 Bioconductor package oligo, with the function read.celfiles. Gene expression was normalized 151 using the package rma, which performs background correction and quantile normalization. 152 Bioconductor annotation packages mogene20sttranscriptcluster.db and pd.mogene.2.0.st were 153 used to annotate at the transcript (probeset) level. Data filtering consisted of removal of 154 probesets without mapping to gene symbols, which ultimately led to 24,996 probesets retained 155 for differential expression analysis. Bioconductor limma package (Ritchie et al. 2015) . Heatmaps depicting significant differentially 165 expressed genes were generated with rows and columns clustered based on Pearson correlation 166 and Euclidean distance, respectively. The Ward agglomeration rule was used for both row and 167 column clustering. Venn diagrams were created using the number of differentially expressed 168 genes with false discovery rate (fdr) < 0.05 for each set of comparisons: each chemical (Rosi, 169 LG268, and TBT) vs. the vehicle (Vh) in differentiated BM-MSCs. 170 Pathway enrichment analyses. Pathway enrichment analyses were performed using a 171 hypergeometric distribution-based test to determine the gene sets (Gene Ontology terms from 172 GO database) over-represented in the lists of significant (fdr< 0.05) differentially expressed 173 genes. Top enriched gene sets between each chemical vs. vehicle comparison included pathways 174 related to brown adipocyte differentiation or mitochondrial biogenesis. We curated two separate 175 lists of genes related to brite adipocyte differentiation or mitochondrial biogenesis and related to 176 osteogenesis to validate the upregulation and downregulation of these pathways with our lists of 177 differentially expressed genes and associated t-test statistics (see Table S2 ).
178
Validation of the enrichment of these curated gene sets was performed based on the Gene 179 Set Enrichment Analysis (GSEA) software (Subramanian et al. 2005 ). Further, we validated the 180 observations from our differential gene and pathway analyses in BM-MSCs exposed to Rosi or 181 TBT with publicly available data (GEO Accession: GSE53004) that examined Rosi or TBT primer sequences are provided in Table S1 . Relative gene expression was determined using the 194 Pfaffl method to account for differential primer efficiencies (Pfaffl 2001 Statistics. All statistical analyses were performed with Prism 5 (GraphPad Software, Inc.,
213
La Jolla, CA). Data are presented as means ± standard error (SE). Four biological replicates of 214 naïve, vehicle, or each chemical-treated cells were processed for the microarray. The n value 215 indicates the number of independent samples that were evaluated. The qPCR data were log-216 transformed before statistical analyses. One-factor ANOVAs (Dunnett's) were performed to 217 analyze the qPCR and phenotypic data. 
231

Chemical treatment modifies nuclear receptor and coregulator expression 232
Our previous work showed that TBT is able not only to stimulate adipocyte 233 differentiation in BM-MSCs, but also to divert osteogenic differentiation toward adipocyte Rosi; yet, Rosi induced more strongly some of the coregulator genes' expressions as indicated by 263 the color intensity of the induced expression ( Figure 2b ). Thus, we examined more closely the (Figure 3c ). There were a total of 164 significantly induced genes 280 in common between all three chemicals. As expected, a set of genes commonly downregulated 281 by all three chemicals were those related to osteogenesis ( Figure S3 ). However, the enrichment 282 of this set had much higher significance for Rosi and TBT (q<0.001) than for LG268 (q=0.05).
283
The significant differential genes for each chemical (compared to Vh-treated cells) were 
293
TBT does not efficaciously induce health-promoting genes 294 We directly compared the enriched pathways between Rosi and TBT and found that 295 mitochondrial biogenesis was significantly upregulated by Rosi compared to TBT (Figure 5a ).
296
To investigate the difference between the transcriptional responses more thoroughly, we curated 297 gene sets, from the literature, related to brite/brown adipocyte differentiation and mitochondrial 298 biogenesis (Table S2 ). Using GSEA software, we determined which curated pathways were (Figure 5b ). To validate whether the genes in the curated genesets related to brite 304 adipocyte differentiation and mitochondrial biogenesis were uniquely upregulated by Rosi, we 305 compared the differential expression of these genes across the three chemicals. Rosi significantly 306 induced most of the genes (e.g. Coq3, Coq9, Acaa2, Pck1) related to mitochondria and 307 metabolism as highlighted in boxed area "a", and TBT-treated cells induced some genes in 308 common with LG268 that were immune-or inflammatory-related (e.g. Ifnar2, IL10, Kng1) and 309 hormone/vitamin (e.g. Irs1, Cnp) as shown in boxed area "b" (Figure 5c ). 310 We used two approaches to validate the finding that TBT induces a transcriptional 311 response distinct from Rosi. First, BM-MSCs were cultured for 5 and 10 days in adipogenic 312 medium to evaluate effects on adipocyte differentiation by the three chemicals. We analyzed by PPARγ and RXR, we included specific ligands for these receptors: rosiglitazone (PPARγ ligand) 348 and LG100268 (RXR ligand) for comparison. Here, we show that, as expected, rosiglitazone,
349
TBT and LG100268 all suppress osteogenesis; but that unexpectedly, TBT has a limited capacity 350 to fully activate PPARγ's transcriptional programs that regulate energy homeostasis.
351
There has been a challenge in understanding the potential for obesogenic effects of 
369
Rosiglitazone induced a distinct spectrum of transcriptional coregulators, relative to TBT.
370
In particular, TBT does not efficaciously induce expression of coregulators related to 371 mitochondrial biogenesis such as Phb2 (see Figure S2 ). Phb2 is required for modulation of 
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